Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.48 |
| ▸ | L3MBTL3 | Q96JM7 | 5/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18711627 | 0.94 | CYP1A2 (0.45) | HRH3L3MBTL3L3MBTL1POLBHSD17B10 | |
| SCHEMBL4550241 | 0.94 | POLB (0.50) | HRH3L3MBTL3L3MBTL1POLBHSD17B10 | |
| SCHEMBL13088446 | 0.90 | POLB (0.55) | HRH3L3MBTL3L3MBTL1POLBHSD17B10 | |
| SCHEMBL13088457 | 0.88 | POLB (0.58) | HRH3L3MBTL3L3MBTL1POLBHSD17B10 | |
| SCHEMBL10075487 | 0.88 | POLB (0.58) | HRH3L3MBTL3L3MBTL1POLBHSD17B10 | |
| SCHEMBL13453747 | 0.88 | POLB (0.58) | HRH3L3MBTL3L3MBTL1POLBHSD17B10 | |
| SCHEMBL13207179 | 0.86 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1 | |
| SCHEMBL15508283 | 0.86 | CYP1A2 (0.52) | HRH3L3MBTL3L3MBTL1POLBHSD17B10 | |
| SCHEMBL600582 | 0.85 | HRH3 (0.52) | HRH3 | |
| SCHEMBL1507253 | 0.82 | HRH3 (0.52) | HRH3L3MBTL3L3MBTL1POLBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| WO-2009143153-A1 | SUBSTITUTED PYRROLIDINE AMIDES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | HRH3 1072/4885L3MBTL3 2777/4885L3MBTL1 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.